Dr. Daixing Zhou is the key driving force of China's Non-Invasive Prenatal Testing (NIPT), and also the pioneer of the Chinese genetic testing market. Making a living away from home in the United States for twenty years, his earlier work in DNA microarrays laid a solid foundation for his transition into the high-throughput sequencing technology field. In 2007, Dr. Zhou was inspired by the “Intrauterine cell-free fetal DNA” research done by Professor Dennis Lo, thus entered the NIPT field and established Berry Genomics in Beijing, China later in 2010, which focused on the clinical application transformation of NGS. Dr. Zhou has penetrative observation and distinctive insights on the genetic testing market in China: